Quick Answer
PTC THERAPEUTICS, INC. reported Research And Development Expense of $455.25 million for the year ending 2025.
- PTC THERAPEUTICS, INC. showed a decrease of -14.8% in Research And Development Expense from 2024 to 2025.
- This data is from PTC THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), PTC THERAPEUTICS, INC.'s Research And Development Expense has grown by 675.9%.
- Historical annual values: Fiscal year 2025: $455.25 million | Fiscal year 2024: $534.48 million | Fiscal year 2023: $666.56 million | Fiscal year 2022: $651.50 million | Fiscal year 2021: $540.68 million | Fiscal year 2020: $477.64 million | Fiscal year 2019: $257.45 million | Fiscal year 2018: $171.98 million | Fiscal year 2017: $117.46 million | Fiscal year 2016: $117.63 million | Fiscal year 2015: $121.82 million | Fiscal year 2014: $79.84 million | Fiscal year 2013: $54.88 million | Fiscal year 2012: $46.14 million | Fiscal year 2011: $58.68 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: